Predictors of ISUP score upgrade in patients with low-risk prostate cancer.


Journal

Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356

Informations de publication

Date de publication:
Jun 2021
Historique:
pubmed: 31 7 2020
medline: 22 5 2021
entrez: 31 7 2020
Statut: ppublish

Résumé

The literature contains few studies that focus on the relationship between International Society of Urological Pathology (ISUP) score upgrade and complete blood count (CBC) parameters for patients with low-risk prostate cancer and studies achieved inconclusive results. We retrospectively analyzed our institutional database for patients with prostate cancer who underwent radical prostatectomy (RP) between 1994 and 2017. In total, we included 633 patients with low-risk prostate cancer in the study. We investigated the effects of clinicopathologic factors on ISUP score upgrade. Moreover, we compared RP pathologic outcomes between the patients with and without ISUP score upgrade. The mean age and follow-up periods were 61.09±6.61 years and 41.9±1.8 months, respectively. ISUP score upgrade was observed in 207 patients (32.7%). In multivariate analysis, high prostate-specific antigen (PSA) density and percentage of positive cores were found to be significantly associated with ISUP score upgrade ( Approximately one-third of the patients in our series had ISUP score upgrade in RP pathology. PSA density and the percentage of positive cores were found to be the factors significantly associated with ISUP score upgrade. CBC-related factors had no effect on ISUP score upgrade.

Identifiants

pubmed: 32727308
doi: 10.1177/0300891620943953
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

254-260

Auteurs

Hakan Bahadir Haberal (HB)

Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey.

Meylis Artykov (M)

Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey.

Berk Hazir (B)

Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey.

Burak Citamak (B)

Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey.

Mesut Altan (M)

Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey.

Sertac Yazici (S)

Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey.

Bulent Akdogan (B)

Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey.

Haluk Ozen (H)

Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH